Brown Vance R 4
4 · BOSTON SCIENTIFIC CORP · Filed Feb 17, 2026
Research Summary
AI-generated summary of this filing
Boston Scientific (BSX) EVP Vance R. Brown Exercises Options, Receives Awards
What Happened
Vance R. Brown, EVP, General Counsel and Corporate Secretary of Boston Scientific (BSX), exercised/converted derivative awards and received new awards on Feb 12, 2026. The filing shows conversion/exercise of 1,442 derivative shares (priced at $0.00) and grant/award entries of 7,420 and 17,510 shares (derivative/RSU-type awards). To satisfy tax withholding, 488 shares were surrendered/disposed at $74.12 each, yielding about $36,171. These actions are primarily awards and an exercise/conversion rather than an open-market sale or purchase.
Key Details
- Transaction date: February 12, 2026; Form 4 filed Feb 17, 2026 (appears one business day late for a Feb 12 transaction).
- Exercises/conversions: 1,442 shares @ $0.00 (reported as derivative exercise/conversion, code M).
- Tax withholding: 488 shares disposed @ $74.12 = $36,171 (code F).
- Grants/awards: 7,420 and 17,510 shares reported as awards/grants @ $0.00 (code A).
- Shares owned after transaction: Not specified in the provided filing details.
- Transaction codes: M = option/derivative exercise or conversion; F = payment of tax liability via share surrender; A = grant/award.
Context
- The exercise/conversion at $0.00 plus immediate surrender of 488 shares to cover taxes indicates a cashless-like tax withholding rather than an open-market sale for investment purposes.
- Footnotes clarify these are restricted stock units (RSUs) or option awards: RSUs represent the company’s commitment to issue one share per unit; some RSUs/options vest in installments — certain RSUs issue in four equal annual installments beginning Feb 12, 2025 or Feb 12, 2027, and the option grant vests in four equal annual installments beginning Feb 12, 2027 (see filing footnotes F1–F4).
- These entries are routine award/vesting and tax-withholding actions; they are informational and do not, by themselves, indicate the insider's market view.
Insider Transaction Report
- Exercise/Conversion
Common Stock
[F1]2026-02-12+1,442→ 34,893 total - Tax Payment
Common Stock
2026-02-12$74.12/sh−488$36,171→ 34,405 total - Exercise/Conversion
Restricted Stock Units
[F1][F2]2026-02-12−1,442→ 2,886 totalExp: 2028-02-12→ Common Stock (1,442 underlying) - Award
Restricted Stock Units
[F1][F3]2026-02-12+7,420→ 7,420 totalExp: 2030-02-12→ Common Stock (7,420 underlying) - Award
Stock Option (Right to Buy)
[F4]2026-02-12+17,510→ 17,510 totalExercise: $74.12Exp: 2036-02-12→ Common Stock (17,510 underlying)
Footnotes (4)
- [F1]Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.
- [F2]Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 12, 2025, the first anniversary of the date of grant.
- [F3]Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 12, 2027, the first anniversary of the date of grant.
- [F4]Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 12, 2027, the first anniversary of the date of grant.